Serina Therapeutics, Inc. has released its financial results for the third quarter of 2026, showcasing advancements in its Parkinson's disease treatment, SER-252. The company is moving forward with its clinical trials, which could have significant implications for both its future and the broader pharmaceutical industry.
Background
Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing drug products for neurological diseases and other indications. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. Serina is publicly traded on the NYSE American under the ticker symbol SER.
What the Filing Says
In the recent 8-K filing dated November 12, 2026, Serina announced its financial results for the quarter ending September 30, 2026. The company reported a net loss of $7.9 million, or $(0.31) per share, compared to a net loss of $4.7 million, or $(0.45) per share for the same period in 2025. Operating expenses increased to $8.0 million from $6.4 million year-over-year.
Additionally, the filing highlighted that the independent Safety Monitoring Committee has recommended advancing SER-252 to Cohort 2 of its clinical trial for Parkinson's disease. Dosing in this cohort has already begun, and topline data is expected in the first half of 2027.
Impact
The advancements in SER-252 could significantly affect patients suffering from Parkinson's disease, offering a potential new treatment option. The pharmaceutical industry, particularly companies focused on neurological treatments, may need to reevaluate their strategies in light of Serina's progress and the promising results from SER-252's trials.
What's Next
The filing does not specify what happens next beyond the ongoing trials for SER-252. However, the company is expected to provide further updates as new data becomes available, particularly following the completion of dosing in Cohort 2.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










